In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Cytosorbents (CTSO), with a price target of $14.00. The company’s shares closed last Wednesday at $9.61.
According to TipRanks.com, McCarthy is a top 100 analyst with an average return of 37.1% and a 53.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytosorbents with a $14.67 average price target, a 53.0% upside from current levels. In a report issued on July 14, H.C. Wainwright also maintained a Buy rating on the stock with a $14.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.74 and a one-year low of $3.49. Currently, Cytosorbents has an average volume of 617.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
